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Abstract Mental and neurological disorders are increasingly
prevalent and constitute a major societal and economic burden
worldwide. Many of these diseases and disorders are
characterized by progressive deterioration over time, that
ultimately results in identifiable symptoms that in turn dictate
therapy. Disease-specific symptoms, however, often occur late
in the degenerative process. A better understanding of
presymptomatic events could allow for the development of
new diagnostics and earlier interventions that could slow or
stop the disease process. Such studies of progressive neuro-
degeneration require the use of animal models that are
characterized by delayed or slowly developing disease
phenotype(s). This brief review describes several examples
of such animal models that have recently been developed with
relevance to various neurological diseases and disorders, and
delineates the potential of such models to aid in predictive
diagnosis, early intervention and disease prevention.
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Introduction
Mental and neurological disorders are increasingly preva-
lent and constitute a major societal and economic burden
worldwide. The impact of these disorders has traditionally
been underestimated by epidemiological data that have
relied on mortality rather than morbidity. According to the
World Health Organization mental and neurological dis-
orders are responsible for only about 1 % of deaths but
account for almost 11% of the global disease burden [1].
Further, due to increased life expectancy and the aging of
general populations in both developed and developing
countries this number is expected to rise to 14.7% by 2020
[1]. Many of the most socially and economically devastating
neurological diseases and disorders are characterized by
progressive neurodegeneration. The prevalence of some of
the most common of these diseases in the United States is
depicted in Fig. 1. By extrapolation the prevalence world-
wide is probably about 20x that of the USA.
Symptoms of many forms of progressive disease often
appear in late adolescence or early adulthood and then
become increasingly severe with increasing age. The
neurodegenerative process however, usually begins long
before the onset of clinically diagnosed symptoms. For
example, it is estimated that up to 60% of the dopaminergic
neurons in the substantia nigra need to be lost before the
first clinical signs of Parkinson’s disease appear [3]. Thus,
in many cases a precipitating event occurring much earlier
in life, often around the time of birth or in early childhood,
appears to initiate a degenerative cascade that proceeds
undetected for some time prior to the onset of clinical signs.
Presymptomatic detection of disease represents, therefore, a
largely unexplored opportunity for therapeutic intervention.
By detecting the disease process earlier, and initiating
appropriate therapy to arrest the neurodegenerative process
prior to the onset of symptoms, the disease process could be
slowed or even stopped long before the patient becomes
debilitated by both the primary disease process and
secondary complications. This general concept is depicted
in Fig. 2. While conceptually simple, such an approach to
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preventative therapy is by no means easy to implement.
Even if pre-symptomatic biomarkers relevant to individual
diseases could be identified, health budgets can not
possibly support sustainable screening of all members of
the population, and the incidence of these diseases is too
large to permit accurate presymptomatic risk analysis
(eg. Framingham). Further, most neurological diseases
are presumed to not result from a single precipitating
event, but rather arise from a complex interaction
between initiating stimuli, genetic predisposition, envi-
ronmental factors and lifestyle [4]. None-the-less, the
overall goal of identifying disease earlier is both socially
and economically responsible and should be vigourously
pursued. Genetic predispositions and gene-environment
interactions can be identified for individual diseases
through careful study, and it is quite conceivable that the
early indicators of neurodegeneration may be common or
overlap between different diseases. This latter point gives
rise to hope, and is supported by the knowledge that many
neurodegenerative diseases demonstrate co-morbidity. In
other words patients with a diagnosis of one disease often
show signs of others. For example schizophrenia patients
often suffer from epilepsy, Parkinson’s disease patients
often develop dementia, and epilepsy patients often
present with cognitive impairment. Thus, while the
ultimate diagnosis of disease reflects the predominant
symptomatology (which in turn dictates treatment), it is
reasonable to assume that disease phenotypes overlap to
some extent and may, therefore, have some common
origin(s).
Understanding the etiology, and initiation, of disease
often relies on animal models, as does the development of
new therapeutic strategies. But while there are a multitude
of animal models that mimic specific features of end-stage
disease for almost all neurological conditions, most of these
models have been created with the aim of identifying new
therapeutants to alleviate symptoms, and hence do not
allow study of the development of disease. Understanding
disease development is the key to identifying early
intervention strategies consistent with the concept in
Fig. 2. There exists, therefore, a largely unmet need to
develop and exploit animal models designed to understand
the origins and progression of neurological disease. This
review will introduce several examples of animal models of
progressive neurodegenerative disease. Because many dis-
eases are neurodevelopmental in origin, those models that
have been developed largely, but not exclusively, involve
altering brain development in experimental animals. The
descriptions below reflect that bias, and are not intended to
be all-encompassing or even to be an exhaustive review of
all such models. They are intended, rather, simply as
examples to illustrate the concept of modeling disease
progression as a means to identify predictive and/or
preventative therapeutic strategies.
Fig. 1 Prevalence in the USA of several important neurological diseases
characterized by progressive neurodegeneration. Numbers are expressed
in thousands (000 s) of persons affected. Data derived from [2]
Fig. 2 Representation of the
concept of progressive neuro-
degeneration and presymptom-
atic therapeutic intervention.
Events, often unidentified, initi-
ate a progressive deterioration of
brain health that continues for
some time prior to the appear-
ance of symptoms associated
with a particular neurological
disease. Traditionally therapy is
initiated at the time of symptom
onset and diagnosis, but earlier
detection of deteriorating brain
health would allow for pre-
symptomatic intervention that
could slow or prevent disease
progression
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Progressive neurodevelopmental models of disease
Brain development
Brain development in mammals is a prolonged process
beginning early in gestation and continuing into young
adulthood. Abnormal development occurs as a result of
changes in cellular processes that normally work in a
delicate functional and temporal sequence. Whether these
changes arise from physical damage or from neurotoxic
insult, the impact of the injury depends upon the organism’s
stage of growth [5, 6]. Generally, periods of rapid
development are more vulnerable to damage and the extent
of a given effect depends in large part on exposure timing.
These critical periods, or “windows” of development have
been divided by Vorhees [5] into four stages (although the
final three have some overlap); namely, 1) implantation and
all events preceding fertilization, 2) organogenesis, 3)
differentiation and specialization of cells, and 4) functional
organization, a period that encompasses both late fetal and
early postnatal life and includes gene and receptor
expression and post-translational modification of proteins
that may be either programmed or be activity-dependent. It
is this fourth developmental phase that manifests the
greatest response to behavioural teratogens and is a
prolonged period of vulnerability [5]. In the rat, the period
from postnatal day (PND) 0 to PND 21 displays a particularly
high rate of differentiation and acceleration of brain growth,
with half of the total cell population forming during this time.
In addition, processes such as synaptogenesis, developmental
cell death (apoptosis), myelination, selective removal of
excess synapses, and maturation of all major neurotransmitter
systems occur at this time [6, 7]. This so-called “brain growth
spurt” is, therefore, a period of particular vulnerability to
neurological insult, and disruptions during this time may be
manifested through a variety of behavioural and pathological
abnormalities. In humans, the equivalent period occurs
roughly between the third trimester of gestational develop-
ment and the second year of life [8].
Neonatal models of epileptogenesis
Epilepsy is a complex, symptomatically-defined cluster of
disorders that affects 1–1.5% of the population worldwide
[9]. Characterized by recurrent seizures manifesting either
as motor convulsions or abnormalities in electroencephalo-
graphic (EEG) recordings, epilepsy can be either general-
ized (affecting the whole brain) or partial (affecting discrete
brain regions such as the temporal lobe). Partial epilepsy
may or may not progress to generalized seizures [10].
Epilepsy is also frequently neurodevelopmental in origin,
whereby a strong correlation exists between developmental
CNS trauma (eg. hypoxia, closed head trauma, febrile
seizures) and the subsequent development of seizure
disorders such as temporal lobe epilepsy (TLE) [11]. While
childhood epilepsy is not uncommon, early trauma is often
followed by a latent, or “silent”, period ranging from years to
decades before the onset of epileptic seizures. This delayed
onset is a time when the brain is undergoing progressive
changes in structure and function that ultimately culminate in
seizures, and is referred to as “epileptogenesis” (ie. the
process of becoming epileptic) [10].
The process of epileptogenesis is poorly understood, but
because it is presymptomatic, the epileptogenic period
represents a window in which therapeutic intervention
could slow or even stop the development of epilepsy.
Understanding the process of epileptogenesis and identifi-
cation of potential biomarkers for presymptomatic inter-
vention, however, requires the development of appropriate
animal models, and while there are a number of epilepsy
models that involve chemical or electrical induction of
spontaneous recurrent seizures in adult animals [for review
see 11, 12], modeling epilepsy, and particularly epilepto-
genesis, in neonatal animals has proven more difficult. This
is due, in part, to what superficially appears to be a paradox.
It is well established that the immature brain is more prone
than the adult brain to seizures arising from chemical or
environmental intervention [13–16], probably because of a
difference in the developmental maturation of excitatory
and inhibitory systems [17]. Despite this increased suscep-
tibility to seizure genesis, however, the neonatal brain has
generally been regarded as largely resistant to the develop-
ment of long-term consequences consistent with epilepsy
(eg. spontaneous recurrent seizures, mossy fiber sprouting,
hippocampal cell loss) [18–20], although others have
reported long-lasting consequences of neonatal seizures
particularly when multiple administrations of convulsants
are administered during early development [21, 22].
Of particular relevance to understanding the neuro-
developmental origins of epilepsy and epileptogenesis with
an eye on early intervention, however, are two recently
described rodent models of epilepsy that produce slowly-
developing or delayed onset changes in epilepsy-relevant
morphology, neurochemistry and behaviour. These are the
neonatal inflammation model and the neonatal domoic acid
model; each of which is described in more detail below.
Neonatal inflammation
Recently an interesting model linking neonatal inflamma-
tion and seizure susceptibility has been described [23–25].
Sprague-Dawley rat pups injected intraperitoneally with the
bacterial endotoxin lipopolysaccharide on PND14 demon-
strate enhanced susceptibility to seizures induced by
lithium-pilocarpine, kainic acid (KA) or the GABA
antagonist pentylenetetrazol when challenged at 6–8 weeks
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of age. The effect is antagonized by concurrent administra-
tion of an antibody to tumor necrosis factor α (TNFα). The
authors also investigated whether the same result was
obtained following LPS injection at other stages of develop-
ment, and reported that injections on PND 7 also reduced
seizure threshold, but that LPS injections on PND 1 or PND
20 did not; strongly implicating the second postnatal week of
life as a “critical window” for the lasting effects. A follow-up
paper by the same group described how direct (icv)
injections of the viral mimetic polyinosinic:polycytidylic
acid into PND 14 rat pups produces central inflammation and
also results in a reduced seizure threshold when tested at 7–
8 weeks of age [24]. Thus both peripheral and central
inflammation during the second postnatal week of life in
the rat appears to initiate a chronic neurodegenerative
condition that culminates in reduced seizure threshold.
Neonatal domoic acid
Another neurodevelopmental model of epileptogenesis that
has been described is the neonatal domoic acid model.
Domoic acid is a naturally occurring excitotoxin that is
structurally similar to KA and an analogue of glutamate,
and is recognized as a selective, but not specific, agonist at
the kainate subclass of non-NMDA glutamate receptors
[26, 27]. In the late 1980’s domoic acid was identified as
the causative agent in an outbreak of human toxicity in
which patients experienced dose-dependent neurotoxicity
culminating in seizures and death [28, 29]. One of the
patients who survived subsequently went on to develop
temporal lobe epilepsy [30]. Building on this background of
clinical data, Doucette and co-workers investigated the
response of neonatal rats to very low doses of domoic acid
[16, 31] and in 2004 they described a unique low-grade
seizure response that occurred in rats treated neonatally but
exposed to novel and/or stressful environments as adults
[32]. In addition to manifesting seizures in adulthood, post-
mortem analysis of these animals at 15 months of age
revealed many hallmark features of clinical TLE including
hippocampal cell loss, mossy fiber sprouting (MFS) in the
dentate gyrus and area CA3, and regionally-selective
elevations of the neurotrophin BDNF [32]. Of particular
interest in the context of the current review, however, is that
these changes do not occur at the time of drug administra-
tion (unpublished) but are progressive in nature whereby
younger mature animals (PND75) display less severe MFS
and no loss of hippocampal cells [33] and adolescent rats
(PND 29) show no hippocampal pathology with the
exception of mild atrogliosis [34]. Further confirming the
relevance of this model to understanding epilepsy and
epileptogenesis are two recent reports by Gill et al. [35, 36]
demonstrating alterations in electroencephalographically
(EEG) recorded sleep patterns and reductions in seizure
threshold that accompany selective loss of inhibitory
neurons in the hippocampus. A general overview of the
current understanding of hippocampal epileptogenesis in
this model is shown in Fig. 3.
One obvious deficiency in the neonatal domoate model
at this time, however, is a lack of data on the ability to
predict therapeutic efficacy for current or emerging drugs.
Because the model does not exhibit spontaneous motor
convulsions, typical anticonvulsants are not of immediate
relevance, but other anti-epileptics such as channel modu-
lators or ligands for pharmacologically defined receptors
controlling excitability need to be tested to properly
evaluate the predictive validity of the model in relation to
more established protocols.
Neonatal models of schizophrenia and related disorders
Schizophrenia is a complex and devastating mental disorder
affecting approximately 1% of the general population.
While the term schizophrenia was first introduced by
Eugen Bleuler in 1911, it is believed that the disorder has
been present in all cultures for centuries [37]. Characterized
by impairments in the perception and expression of reality,
the symptoms of schizophrenia are most often categorized
into positive, negative and more recently, cognitive symp-
toms [38]. Schizophrenia is debilitating and results in great
emotional cost to the person afflicted, as well as to friends
and relatives. It also results in great financial cost to the
economy worldwide [39], with the estimated annual cost of
healthcare for those afflicted in Canada alone, being over
$2 billion US [40]. While the outlook for those affected has
improved somewhat, a diagnosis of schizophrenia is still
likely to result in substantial disability and potentially, in
reduced life expectancy due to suicide [41, 42].
Fig. 3 Preliminary schematic depiction of identified changes over
time in a neurodevelopmental rat model of temporal lobe epilepsy.
Low doses of domoic acid during the second postnatal week lead to a
progressive series of changes in hippocampal neurotrophin signaling,
astrogliosis, sprouting of dentate granule cell axons and cell loss, that
are accompanied by changes in cognition, seizure threshold and EEG
although the precise time of onset of each is currently unknown.
Changes depicted are correlative only and not necessarily causally
related. Data derived from [32–36]
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Although schizophrenia has been present for centuries
and progress has been made through research, much about
the disorder is still unknown. This is probably due to the
complexity of the proximal cause(s) of the disorder and the
apparent delay of the onset of definitive symptoms.
Although the cause(s) of schizophrenia is/are not yet
known, a prominent hypothesis is that it is neurodevelop-
mental in origin and arises due to a combination of
environmental factors and genetic susceptibility. According
to this theory, factors which occur long before the formal
onset of the illness (potentially during gestational or early
developmental stages), disrupt normal CNS development in
a way that may lead to severe and long-lasting changes in
the functional integrity of the CNS [43]. Early life events
that have been implicated in a higher than average risk of
developing schizophrenia include maternal illness during
gestation [44], obstetric complications [45, 46] and toxin
exposure [47]. Such events can lead to subtle alterations in
the functioning of the CNS which may result in an
increased vulnerability to environmental triggers later in
life [48]. However, while environmental factors likely cause
an individual to be more susceptible to the illness or play a
role in triggering the onset of symptoms, specific genetic
vulnerabilities also appear to contribute to the manifestation
of schizophrenia. Although the prevalence of schizophrenia
may only be up to 1% in the general population, the
prevalence of the disorder is much higher in those who
have a schizophrenic relative. Additionally, though the
disorder can occur in people who have no family history of
its presence, the risk increases dramatically with the degree
of genetic closeness to a person who is afflicted [37].
Avariety of genes have been associated with schizophrenia
including neuregulin (NRG1) [49], dysbindin (DTNBP1)
[50], Catechol-O-methyl transferase (COMT) [51] and
DISC1 [52], and consequently a number of genetically-
based animal models exist for studying schizophrenia. A
thorough discussion of these models and their use in
schizophrenia research is beyond the scope of this review,
but has been discussed in detail elsewhere [for review see 53].
Of more relevance to the current review are several well
characterized and/or emerging rodent models of schizo-
phrenia that involve experimental manipulation in the
perinatal period that gives rise to schizophrenia-like
symtomatology that develops over time. Such slowly
progressing animal models provide good platforms for both
understanding disease development and identifying poten-
tial early markers of disease progression.
Lesion models
First proposed by Lipska and co-workers in 1993 [54], the
neonatal ventral hippocampal (NVH) lesion model is one of
the most widely studied animal models of schizophrenia.
By using ibotenic acid (a glutamate agonist) to lesion the
ventral hippocampus of neonatal rats on PND 7 of
development, many aspects of the disorder have been
demonstrated. Compared to controls, rats with lesions
demonstrated a higher degree of activity in response to a
novel environment and/or amphetamine challenge when
tested in early adulthood (PND 56), but not at earlier time
points (PND 35) [54]. Deficits have also been observed in
other behavioural measures including prepulse inhibition
(PPI) [55], latent inhibition (LI) [56], measures of working
memory [57] and social interaction measures, with rats who
received NVH lesions spending less time in social
interaction as compared to controls [58].
In addition, neurobiological factors such as an increase
in hippocampal dopamine (DA) have also been found [59]
and a number of studies have indicated that antipsychotic
drugs normalize some of the lesion-induced behaviours [54,
60]. In addition to the NVH model, other lesion based
models of schizophrenia have been described including the
neonatal amygdalar lesion model [61] where ibotenic acid
is used to lesion the amygdala on PND 7, and the prefrontal
cortical lesion model [62] which uses ibotenic acid to lesion
the prefrontal cortex in neonatal or adult animals.
Immunological models
Prenatal exposure to infection has also been implicated in
an increased risk of developing schizophrenia in adulthood.
Presently it is believed that the maternal immune response,
particularly the pro-inflammatory cytokines that are re-
leased in such situations, can interfere with the normal
development of the CNS. As such, immunological models
seek to imitate this potential risk factor [63]. Seeking to
elicit the maternal immune response by mimicking viral
exposure, Zuckerman and Weiner created such a
model by injecting pregnant rats with polyriboinosinic-
polyribocytidilic acid (polyI:C). This procedure resulted in
adult animals displaying a variety of schizophrenia-like
anomalies including deficits in PPI [64] and LI [65], as well
as increased sensitivity to the locomotor effects of
amphetamine [66], impairments in novel object recognition
[64] and reduced social interaction [67]. Neuroanatomical
and neurochemical abnormalities have also been observed
including alterations to hippocampal morphology and
increases in striatal DA release [66].
Pharmacological models
Another animal model of schizophrenia proposed by Harris
et al.[68], used the administration of MK-801 (a
glutamate antagonist) to neonatal rats, to produce a
schizophrenia-like phenotype in adulthood. The procedure
involved the administration of two subcutaneous (s.c.)
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injections of 0.5 mg/kg of MK-801 to Sprague-Dawley
rat pups on PND 7. As adults, the animals displayed
reduced volume and neuronal numbers in the hippocam-
pus, and female rats displayed PPI deficits and increased
locomotor activity in the open field [68].
In another study, Kawabe et al. [69] administered 0.2 or
0.4 mg/kg ofMK-801 by i.p. injection, twice daily to neonatal
rats from PND 7–20. It was found that when they reached
adulthood, these animals displayed significant deficits in
radial arm maze (RAM) learning. Interestingly, when adult
animals who had not received the neonatal MK-801 treatment
neonatally were given the same treatment in adulthood, no
changes to RAM performance were noted [69].
In addition to the aforementioned work on NMDA
receptors, neonatal manipulation of non-NMDA receptors
has also been shown to result in schizophrenia-like
symptoms that develop as animals age. In a series of
papers published over the last 10 years, the Csernansky
research group at Washington University in St. Louis has
described how intracerebroventricular (icv) injection of a
sub-convulsive dose of kainic acid on PND 7 induces
delayed histopathology consistent with schizophrenia.
Looking at time points ranging from 8–75 days of age
these authors have described progressive loss of neurons in
the CA1 and CA3 hippocampal subfields [70, 71].
Interestingly, at a low dose of KA cell loss did not begin
until around PND40; mimicking the delayed onset of
schizophrenia, and appeared due to apoptosis rather than
the necrosis typically associated with excitotoxicity [71].
Subsequent papers by the same group have also reported
changes in hippocampal interneuron populations [72] and
hippocampal neurogenesis [73] in this model.
Closely related to these findings are the recent data
emerging from two independent groups that have adminis-
tered domoic acid (DOM) during perinatal development. As
described previously in this review, DOM is a naturally
occurring environmental toxin produced by various marine
organisms such as red algae [74] and has been associated with
human intoxication resulting in neurological damage as well
as being used to induce seizure states in experimental
animals. A 2005 study by Levin and co-workers [75]
revealed that a single prenatal exposure to DOM during
midgestational development (with doses ranging from 0.3–
1.2 mg/kg) produced dose related changes which included an
increase in response latency in a spontaneous alternation task
in the T-maze, as well as an increase in initial activity and a
larger habituation score in the Figure-8 maze. Additionally, a
later study by the same group [76], considered the effect of
administering DOM (0.025–0.1 mg/kg) to rat pups twice per
day, on PND 1 and 2. While the higher doses proved to be
lethal, they did report some effects at lower doses, but these
were less frequently observed than those seen following
DOM exposure during mid-gestation.
In a related series of experiments Doucette et al. [31]
demonstrated that when tested during the neonatal period,
administration of very low doses of DOM to Sprague-
Dawley rats did not alter a number of developmental
milestones but treated rats did display increased conditioned
place preference in an olfactory conditioning paradigm;
confirming that this low dose of DOM (20 μg/kg) was
centrally active at doses that were not overtly toxic. The same
group then went on to administer low-dose DOM throughout
the second postnatal week (PND 8–14) and reported a number
of schizophrenia-like changes in behaviour when the animals
were tested as adults. Treated animals have been shown to
have abnormal responses to novel spatial environments [32]
as well as impairments in prepulse inhibition [77], spatial
cognition [78] and working memory [79]. Alterations in
emotionality (elevated plus maze) as well as changes in
response to novelty and increased sensitivity to nicotine have
also been found in this paradigm [79–81]; as have increased
sensitivity to reward (in a choice task) and psychomotor
agitation (in a novelty conditioning paradigm) and social
withdrawal (unpublished). Interestingly, and potentially of
great importance, the same experimental manipulation (ie.
low dose neonatal domoic acid) also produces a behavioural
phenotype with relevance to partial complex epilepsy
originating in the temporal lobe as described previously in
this review (see above). Because the same drug, administered
during the same neonatal window, results in features of both
epilepsy and schizophrenia, there may be common molecular
origins relevant to both disorders, although in the absence of
further mechanistic data on both models such a conjecture is
hypothetical at this time.
Thus, there are a number of different rodent models that
utilize changes in perinatal brain development resulting in
slowly progressing deterioration of central function relevant
to schizophrenia and related psychiatric disorders.
Prenatal/Neonatal models of movement disorders
Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease
(PD) are two of society’s most prevalent diseases of
progressive motor dysfunction (Fig. 1). Most in vivo studies
of ALS and Parkinson’s disease have examined associated
movement disorders primarily in adult animals. There are
good theoretical reasons and practical reasons for this
emphasis. First, most cases of both diseases in humans are
of the late onset form and are usually sporadic in nature. Gene-
based models in fact have not been able to duplicate early
onset human neurological diseases. For example, the most
common ALS models of the familial (genetic) forms of the
disease, mutant superoxide dismutase (mSOD) and the alsin
protein deletion associated with juvenile ALS 2, do not show
clear behavioural or pathological outcomes until well into
postnatal life, if at all. For mSOD, the rapidly progressive
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G93A mutation only begins so show pathological features at
about 50 days of postnatal life [82]. The G37R variant takes
up to a year to demonstrate behavioural or pathological
deficits [83]. ALS2/alsin -/- mice show almost no disease
phenotype at any age [84]. Similarly, genetic models of PD
usually show few early behavoural or neuronal outcomes [4].
Studies of environmental factors typically use adult
animals (post sexual maturity and older) for a variety of
factors such as ease of handling and testing and toxin
administration. These factors may be one reason why no
good age-dependence animal studies exist for either
disease. In spite of these difficulties, for both ALS and
Parkinson’s disease, there have been some attempts to
probe the impact of some of the toxins studied in adulthood
in prenatal mice. Steryl glucosides, notably those isolated
from the seeds of the cycad palm [85, 86] have been
implicated in a form of ALS that is sometimes linked to the
co-expression of a form of parkinsonism (parkinsonism
dementia complex), thereby forming a spectrum of neuro-
logical disorders termed ALS-PDC [87–89] (see below). A
recent series of experiments by Shaw and Banjo [90] began
to examine the neonatal and postnatal outcomes of steryl
glucoside neurotoxins related to those previously implicat-
ed in ALS-PDC [86, 91] and shown to cause neuro-
degeneration following adult exposure [92]. This study
administered these toxins to pregnant dams during the
period of greatest differentiation of the nigro-striatal
system, and also sought to determine if the impact of a
second toxin exposure in adulthood was influence by the
prenatal one. Finally, the experiments separated male from
female mice to determine the role that sex might play.
Prenatal exposure to steryl glucoside toxins showed that
mice exposed in utero had greater body weights that persisted
throughout life and showed behavioural deficits associated
with damage in the nigro-striatal system. Male mice were
more profoundly impacted than females. A second adult toxin
exposure had more negative impacts on the nigro-striatal
system than in the spinal cord. These data mirror the earlier
findings of Barlow et al. [93] that exposure of pregnant dams
to the pesticides maneb and paraquat caused damage to the
nigro-striatal system, that the effects were sex specific as
above, and that an adult toxin exposure was more likely to
trigger a Parkinson’s phenotype.
The results of these experiments reaffirm the notion that
prenatal and likely neonatal life are potentially crucial
periods that might set the conditions for later neurodegen-
erative disorders.
Slowly progressing adult models of movement disorders
There are a variety of adult models of ALS and Parkinson’s
disease, based generally on genetic or environmental models.
For ALS, the primary genetic models are based on
various mutations of SOD that produce, with different time
courses, many of the features of ALS, including progressive
motor deficits and the loss of spinal cord motor neurons.
Alsin mutations have not produced particularly profound
ALS phenotypes to date. The mSOD model has been used
with great success in isolating the putative stages of
neurodegeneration which is now believed to have a partial
origin in the loss of neuromuscular junction endplates in
mutant animals [94]. A number of studies with the mSOD
model using various therapeutic drugs have shown modest
delays in symptom onset and life expectancy [95–99].
However, no single agent or “drug cocktail” to date has
provided lasting protection or actually delayed the eventual
outcomes of motor neuron death [100].
Environmental links to ALS have arisen from a
variety of sources, with the most well studied cases
related to the cluster of ALS-PDC found on Guam and
elsewhere in the Western Pacific during the 1950s and
1960s. As described previously, the strongest epidemio-
logical correlate for ALS-PDC was the consumption of a
local food product, the seeds of the cycad palm [88, 89].
Cycad seed has been shown to contain a variety of
neurotoxic compounds, some of them water insoluble.
Mice fed washed cycad seed flour exhibit a progressive
form of motor neuron loss accompanied by motor
behavioural deficits. These are later followed by gait
disorders associated with pathological outcomes in the
nigro-striatal system, the latter including the loss of
tyrosine hydroxylase and apoptosis in the striatum.
Increases in reactive astrocytes and microglia were
components of both areas. In marked contrast, rats fed
cycad seed flour showed profound parkinsonism outcomes
of gait disturbances that initially presented unilaterally,
later freezing, and highly significant losses of neurons in
substantia nigra. Treated rats did not show any losses of
motor neurons in the spinal cord [101] (Table 1).
Mice fed the putative neurotoxic factor in cycad, variant
steryl glucosides, showed many of the same features as
those fed cycad [92]. Preliminary studies using steryl
glucosides in rats suggests that they exhibit only parkin-
sonism phenotypes (unpublished).
Attempts have been made to duplicate ALS-PDC in its
various forms in monkeys [85] using the free plant amino
acid, beta-methyl amino alanine (BMAA) and earlier by
Dastur and colleagues using washed and unwashed cycad
seed flour [102]. The Spencer results [85] have not been
repeated and the original data could not be duplicated in
mice fed BMAA [103, 104].
In regard to Parkinson's disease, a great variety of studies
have focused on either genetic links to the disease,
including mutations in alpha-synuclein and others [105,
106], or to various toxins linked to some forms of
EPMA Journal (2010) 1:217–227 223
parkinsonism. These models rarely produce full blown
Parkinson's disease phenotypes. The latter have included
toxins such as MPTP, linked originally to rapid parkinson-
ism onset following the use of a synthetic opioid, 6
hydroxydopamine, proteasome inhibitors [107–109], and
various pesticides as well as cycad and steryl glucosides as
cited above. Continuous delivery of MPTP via a pump or
slowing MPTP excretion by concomitant administration of
probenecid has been used to produce a slower neurodegen-
erative process [110–112].
One of the more interesting animal models of Parkin-
son's disease is based on the cluster on the island of
Guadeloupe linked to annonacin neurotoxins contained in
the fruit of the soursop (summarized in Shaw and
Hoglinger [4]. Here, as in ALS-PDC, an environmental
neurotoxin epidemiologically linked to a human neurode-
generative disease condition can duplicate many of the
disease phenotypes in in vivo models.
Outlook
Animal models that allow examination of the develop-
mental processes underlying neurodegenerative disease
represent an important opportunity to develop therapies
directed at prevention or amelioration of the disease
phenotype. As stated at the beginning of this review, the
task of identifying pre-symptomatic markers of disease in
human populations and then implementing appropriate
screening and treatment options is daunting, but poten-
tially of enormous value. One obvious opportunity is
identification of early biomarkers of disease that could
translate rapidly into diagnostic and clinical settings.
Another is identification of early targets common to
multiple disease processes. While seeming fanciful to
some, some of the examples described above give
credence to this notion. In some of the models described
herein, both neonatal inflammation and neonatal gluta-
matergic stimulation have been used to model both
epilepsy and schizophrenia; two conditions known to
exhibit co-morbidity but currently treated with widely
differing classes of drugs. Administration of steryl
glucosides results in symptoms common to both ALS
and Parkinson’s disease with the relative proportion of
phenotype influenced by the species of choice (mice
versus rats). At this stage it is too early to know to what
extent the relevant disease processes overlap and which
precise molecular events result in each disease phenotype,
but better understanding of early disease progression,
combined with improved epidemiological data on appro-
priate risk factors, represents an avenue for improving
predictive and personalized therapy.
Table 1 Comparison of features of ALS-PDC of Guam with animal
models of the disorder. The various features of the Guamanian
spectrum of disorders are compared to two rodent models fed flour
made from seeds of the local cycad palm, Cycas micronesica. Cycad
consumption is still considered to be the strongest epidemiological
link to ALS-PDC [88, 89]. Both model systems have also examined
dietary exposure to isolated cycad neurotoxins, notably two variant
steryl glucoside, B-sitosterol B-D glucoside (BSSG) and stigmasterol
glucoside (SG). Combined, the two models faithfully reproduce the
salient behavioural and pathological features of the ALS-PDC spectrum
Disease outcomes ALS-parkinsonism
dementia complex
Rodent models of ALS-PDC (cycad or steryl glucoside)
Behavioural changes motor function Expresses as ALS, PD, or both for
motor function losses
Mice: ALS-phenotype is dominant; Rats: parkinsonism only
Cognitive function Dementia accompanies parkinsonism Cognitive decline on various memory tests both models
Olfactory function ALS-PDC shows early olfactory
disturbance
Mice fail to discriminate odours
Motor neuron loss Yes, all levels of motor system Mice, yes; Rats, no.
Nigro-striatal neuron loss PDC Mice: significant but not dominant feature; Rats: significant
losses of cells in SNpc and striatum
Loss of neurons in hippocampus/cortex Features of PDC Mice at late stages
Expression of hyperphosphorylated tau Both ALS and PDC Mice at late stages in lumbar spinal cord motor neurons with
steryl glucoside feeding
Α-synuclein expression Approx. 20% PDC cases Rats with cycad
TDP-43 translocation Noted Mice at late stages in lumbar cord motor neurons with steryl
glucoside feeding
Dopamine loss PDC Mice and rats
D2 receptor upregulation; DAT
down regulation
unknown Mice; Rats unknown
Increases in reactive astrocytes ALS-PDC Both mice and rats in various affected regions of CNS
Increases in microglial proliferation ALS-PDC Both mice and rats in various affected regions of the CNS
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Conclusion
Further development and analysis of slowly progressing
animal models of neurological disease is an area of
increasing interest and considerable potential. Understand-
ing the origins, molecular targets, and internal and external
modifiers of disease progression through the use of such
models constitutes a promising new approach to new
therapy development, and if factors common to multiple
diseases can be discovered the value, and practicality, of
pre-symptomatic intervention will be greatly enhanced.
Thus, continued study and development of slowly pro-
gressing animal models of disease appears to be a viable
option for advancing the agenda of predicting and prevent-
ing, rather than simply treating, some of society’s most
devastating neurological conditions.
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